-
1.发明授权Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof 有权结合蛋白质，包括特异性结合CD154的抗体，抗体衍生物和抗体片段及其用途公开(公告)号：US08293237B2
公开(公告)日：2012-10-23
申请号：US12532517
申请日：2008-03-21
申请人： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
发明人： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
IPC分类号： A61K39/395 , C07K16/00 , C12N15/63 , C12N5/10 , C12P21/02
CPC分类号： C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
摘要翻译： 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。
-
2.发明申请BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF 有权结合蛋白质，包括抗体，抗体衍生物和抗体片段，特别是CD154及其用途公开(公告)号：US20100104573A1
公开(公告)日：2010-04-29
申请号：US12532517
申请日：2008-03-21
申请人： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
发明人： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/02 , A61P29/00 , A61P37/00
CPC分类号： C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
摘要翻译： 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。
-
公开(公告)号：US08409810B2
公开(公告)日：2013-04-02
申请号：US12093658
申请日：2006-11-17
申请人： Yen-Ming Hsu , Lihe Su
发明人： Yen-Ming Hsu , Lihe Su
CPC分类号： G01N33/6863 , G01N33/86
摘要： The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.
摘要翻译： 本发明提供了确定血小板聚集的方法，在给予CD40L结合部分时确定凝血敏感性的方法，以及与其相关的试剂盒。
-
公开(公告)号：US20090220998A1
公开(公告)日：2009-09-03
申请号：US12093658
申请日：2006-11-17
申请人： Yen-Ming Hsu , Lihe Su
发明人： Yen-Ming Hsu , Lihe Su
IPC分类号： G01N33/567
CPC分类号： G01N33/6863 , G01N33/86
摘要： The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.
摘要翻译： 本发明提供了确定血小板聚集的方法，在给予CD40L结合部分时确定凝血敏感性的方法，以及与其相关的试剂盒。
-
公开(公告)号：US20140369940A1
公开(公告)日：2014-12-18
申请号：US14128497
申请日：2012-06-22
申请人： Andreas Weihofen , Jan Grimm , Cristoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
发明人： Andreas Weihofen , Jan Grimm , Cristoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
CPC分类号： C07K16/18 , A61K47/6849 , C07K2317/34 , C07K2317/565 , G01N33/6896 , G01N2333/47 , G01N2800/28 , G01N2800/2828 , G01N2800/2835
摘要： Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供抗人α-突触核蛋白特异性结合分子，例如抗体或抗原结合片段，其变体或衍生物，作为与其相关的方法。 还提供了结合人α-突触核蛋白上的特异性N末端和C-末端表位的抗人α-突触核蛋白结合分子。 本文所述的结合分子可分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US09580493B2
公开(公告)日：2017-02-28
申请号：US14128497
申请日：2012-06-22
申请人： Andreas Weihofen , Jan Grimm , Christoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
发明人： Andreas Weihofen , Jan Grimm , Christoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
IPC分类号： A61K39/395 , C12P21/08 , C07K16/18 , G01N33/68
CPC分类号： C07K16/18 , A61K47/6849 , C07K2317/34 , C07K2317/565 , G01N33/6896 , G01N2333/47 , G01N2800/28 , G01N2800/2828 , G01N2800/2835
摘要： Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供抗人α-突触核蛋白特异性结合分子，例如抗体或抗原结合片段，其变体或衍生物，作为与其相关的方法。 还提供了结合人α-突触核蛋白上的特异性N末端和C-末端表位的抗人α-突触核蛋白结合分子。 本文所述的结合分子可分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.048 秒)
